Viking Pharmaceuticals Viking Therapeutics, Inc. (NASDAQ: VKTX, VKTXW) was founded in 2012 and is headquartered in San Diego, California, with 12 full-time employees. It is a clinical-stage biopharmaceutical company focusing on the development of new and first-class metabolism And endocrine disorders treatment drugs, Viking’s 3 products have global exclusive patents.
Viking Therapeutics (VKTX):
Viking Therapeutics is a clinical-stage biopharmaceutical company, focusing on the development of drugs for the treatment of metabolic and endocrine disorders.
Viking Therapeutics’ first candidate product-VK5211 , an oral non-steroidal selective androgen receptor modulator with high safety and tolerability. It is currently being treated for recovery from non-selective hip fracture surgery In the phase II clinical development phase of the patients; in the phase I clinical phase for improving lean physique; in the pre-clinical development phase to improve bone mineral density, bone mineral content, and bone strength.
Other product candidates of Viking Therapeutics also include-VK2809 , an oral, thyroid hormone receptor β tissue and receptor subtype selective agonist, currently in phase II clinical treatment for patients with hypercholesterolemia and fatty liver Stage; at the same time in the treatment of patients with glycogen storage disease type Ia clinical stage.
Other product candidates from Viking Therapeutics also include-VK0214 (TRSS) , which is in the preclinical stage for the treatment of X-linked adrenal leukodystrophy.
VK0612-The world’s largest healthcare challenge. Type 2B diabetes can be treated orally. It is currently in phase II clinical trials. Preliminary clinical data shows that VK0612 has the potential to provide a large amount of blood glucose lowering effect. Compared with the existing treatments for type 2 diabetes patients, it is a safer and more convenient treatment.
Viking Therapeutics (VKTX) investment:
Viking Therapeutics (VKTX) was listed on Nasdaq on April 29, 2015 (with EVA one day) , with an issue price of US$8, 3 million shares issued, and US$24 million in capital.